Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis
Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis
Abstract We previously found that type 2 immunity promotes COVID-19 pathogenesis in a mouse model. To test relevance to human disease we used electronic health record databases and determined that patients on dupilumab (anti-IL-4Rα monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.
Donlan A.、Mallawaarachchi I.、Loomba J.、Preissner R.、Sasson J.、Petri W.A.
Division of Infectious Diseases and International Health, Department of MedicineDepartment of Public Health Sciences, University of Virginia School of MedicineIntegrated Translational Health Research Institute (iTHRIV)Science-IT and Institute of Physiology, Charit¨| ¨C Universita??tsmedizin Berlin, corporate member of Freie Universita??t Berlin, Humboldt-Universita??t zu Berlin, and Berlin Institute of HealthDivision of Infectious Diseases and International Health, Department of MedicineDivision of Infectious Diseases and International Health, Department of Medicine||Department of Pathology, University of Virginia School of Medicine
医学研究方法预防医学药学
Donlan A.,Mallawaarachchi I.,Loomba J.,Preissner R.,Sasson J.,Petri W.A..Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis[EB/OL].(2025-03-28)[2025-05-16].https://www.medrxiv.org/content/10.1101/2022.03.30.22273174.点此复制
评论